Genetic factors predicting response to interferon treatment for viral hepatitis C

Gut

Volumn 57, Issue 4, 2008, Pages 440-442

  Stärkel, Peter ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; GAMMA INTERFERON; JANUS KINASE; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; INTERFERON;

ANTIVIRAL THERAPY; CELLULAR IMMUNITY; DRUG EFFICACY; ETHNICITY; GENE EXPRESSION; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; IMMUNOREGULATION; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; GENETICS; PROGNOSIS;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; INTERFERONS; PROGNOSIS; TREATMENT OUTCOME;

EID: 41149144130     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.137646     Document Type: Note

References (28)

1. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pre-treatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-6
2. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004;39:880-90.
3. Schott E, Witt H, Hinrichsen H, et al. Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. J Hepatol 2007;46:372-80.
4. Persico M, Capasso M, Russo R, et al. Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Gut 2008;57:507-15.
5. Ilangumaran S, Ramanathan S, Rottapel R. Regulation of the immune system by SOCS family adaptor proteins. Sem Immunol 2004;16:351- 65.
6. Yoshimira A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007;7:454-65.
7. Platanias LC. Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat Rev Immunol 2005;5:375-386.
8. Frese M, Schwarzle V, Barth K, et al. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002;35:694-703.
9. Guo JT, Bichko VV, Seeger C. Effect of α interferon on the hepatitis C virus replicon. J Virol 2001;75:8516-8523.
10. Larkin J, Jin L, Farmen M, et al. Synergistic antiviral activity of human interferon combinations in the hepatitis C virus replicon system. J Interferon Cytokine Res 2003;23:247-257
11. Tan H, Derrick J, Hong J, et al. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. J Interferon Cytokine Res 2005;25:632-649.
12. Blindenbacher A, Duong FH, Hunziker L, et al. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of trangenic mice. Gastroenterology 2003;124:1465-75.
13. Duong FH, Filipowicz M, Tripodi M, et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 2004;126:263-77.
14. Bode JG, Ludwig S, Ehrhardt C, et al. IFN-α antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003;17:488-490.
15. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-Stat pathway. J Virol 1999;73:8469-75.
16. Asselah T, Bieche I, Narguet S, et al. Liver gene expression signature to predict response to peintgylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008;57:516-24.
17. Hunter DJ, Kraft P. Drinking from the fire hose - statistical issues in genomewide association studies. N Engl J Med 2007;357:436-9.
18. Walsh MJ, Jonsson JR, Richardson MM, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006;55:529-35.
19. Huang Y, Feld JJ, Sapp RK, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007;132:733-44.
20. Huang Y, Yang H, Borg BB, et al. A functional SNP of interferon-gamma gene is important for interferon alpha-induced and spontaneous recovery from hepatitis C virus infection. Proc Natl Acad Sci USA 2007;104:985-90.
21. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003;112:978-80.
22. Li W, Liang X, Kellendonk C, et al. Stat3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem 2002;277:28411-7.
23. Wuestefeld T, Klein C, Streetz KL, et al. Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Biol Chem 2003;278:11281-8.
24. Haga S, Terui K, Zhang HQ, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest 2003;112:989-98.
25. Hosui A, Ohkawa K, Ishida H, et al. Hepatitis C virus core potein differently regulates the Jak-Stat signalling pathway under interleukin-6 and interferon-gamma stimuli. J Biol Chem 2003;178:28562-71.
26. Basu A, Meyer K, Lai KK, et al. Microarray analyses and molecular profiling of Stat3 signaling pathways induced by hepatitis C virus core protein in human hepatocytes. Virology 2006;349:347-58.
27. Stärkel P, De Saeger C, Leclercq I, et al. Deficient Stat3 DNA-binding is associated with high Pias3 expression and a positive anti-apoptotic balance in human end-stage alcoholic and hepatitis C cirrhosis. J Hepatol 2005;43:687-95.
28. Stärkel P, De Saeger C, Leclercq I, et al. Role of signal transducer and activator of transcription 3 in liver fibrosis progression in chronic hepatitis C-infected patients. Lab Invest 2007;87:173-81.